Form 4: Precision BioSciences CEO Sells Shares for Tax Cover

Precision BioSciences CEO Michael Amoroso sold shares to cover tax obligations following the vesting of Restricted Stock Units.

Summary

• Michael Amoroso, President and CEO of Precision BioSciences Inc. (DTIL), reported transactions involving the company's common stock.
• On November 2, 2025, 9,444 Restricted Stock Units (RSUs) vested and settled, representing a contingent right to receive one share of common stock per RSU.
• These RSUs were granted on November 2, 2022, and vested in three substantially equal annual installments, with full vesting occurring on November 2, 2025.
• On November 3, 2025, Mr. Amoroso sold 3,409 shares of common stock at a price of $6.49 per share.
• The sale was a 'sell-to-cover' transaction, executed pursuant to a Rule 10b5-1 plan adopted on August 2, 2024, solely to cover tax withholding obligations related to the RSU vesting.
• Following these transactions, Mr. Amoroso beneficially owns 115,575 shares of common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While an insider sale can sometimes be viewed negatively, this transaction is explicitly a 'sell-to-cover' for tax obligations, executed under a pre-planned 10b5-1 arrangement. This context mitigates any negative interpretation, as it's a routine part of executive compensation rather than a discretionary sale indicating a lack of confidence.

Positives

• The vesting of 9,444 Restricted Stock Units indicates continued service and performance by the President and CEO, Michael Amoroso.
• The sale was pre-planned under a Rule 10b5-1 plan, indicating a structured approach to managing equity compensation and tax liabilities.

Negatives

• The sale of 3,409 shares by an insider, even for tax purposes, represents a reduction in direct ownership, which could be perceived negatively by some investors.

Future Outlook

NA

Industry Context

This transaction is a routine insider filing (Form 4) detailing the exercise and sale of equity compensation. It does not provide broader insights into industry trends or competitive positioning, but rather reflects standard executive compensation practices within the biotechnology sector.

Stakeholder Impact

• Shareholders: The sale of shares for tax purposes is a common occurrence and generally has a minimal impact on the overall share structure. It does not signal a change in management's confidence in the company's future.
• Employees: The vesting of RSUs and subsequent tax-related sale is a standard component of executive compensation, reflecting the company's compensation structure.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction involving the vesting of Restricted Stock Units and a subsequent 'sell-to-cover' sale for tax purposes, executed under a Rule 10b5-1 plan. Such transactions are common and generally do not reflect a change in the insider's outlook on the company's fundamentals or future prospects. Therefore, this specific filing alone does not provide sufficient new information to warrant a change from a 'hold' recommendation, assuming no other material information is available.

Keywords

Precision BioSciences, DTIL, Michael Amoroso, Insider Trading, Form 4, Restricted Stock Units, RSU Vesting, Sell-to-Cover, Rule 10b5-1 Plan, Biotechnology, Executive Compensation